Pharmacogenetics of β2-Agonists  by Hizawa, Nobuyuki
Allergology International Vol 60, No3, 2011 www.jsaweb.jp 239
Pharmacogenetics of2-Agonists
Nobuyuki Hizawa1
ABSTRACT
Short-acting β2-agonists (SABAs) and long-acting β2-agonists (LABAs) are both important for treatment of
asthma and chronic obstructive pulmonary disease (COPD) because of their bronchodilator and bronchopro-
tective effects. However, the use of these agonists, at least for asthma, has generated some controversy be-
cause of their association with increased mortality. Pharmacogenetics is the study of genetically determined
variation in response to medications, which might prove useful for target therapies in highly responsive pa-
tients, especially for more expensive therapies or those with increased risk of side effects. Variation in re-
sponse to both SABAs and LABAs has been observed in patients with polymorphisms in the β2 adrenoceptor
gene (ADRB2). This review summarizes results from various studies on the possible relationship between
ADRB2 polymorphisms and the bronchodilator or bronchoprotective effects of inhaled β2-agonists. By assess-
ing the ADRB2 genotype, the hope is that it will be possible to predict the responsiveness to chronic admini-
stration of β2-agonists. Genetic testing, however, is of limited usefulness at this stage for ADRB2 because the
common variants identified thus far account for only a small proportion of the variation observed for given re-
sponses. Carefully performed and adequately powered clinical trials continue to be important for achieving the
goal of pharmacogenetic approaches to therapy.
KEY WORDS
asthma, beta-2 adrenergic receptor, chronic obstructive pulmonary disease (COPD), genetic polymorphism
INTRODUCTION
Beta-adrenergic receptors are important drug targets
in asthma and COPD. Inhaled β-receptor agonists re-
main among the mostly commonly prescribed medi-
cations to treat airflow obstruction in adults. How-
ever, persistent stimulation of β2-adrenergic receptor
(β2AR) pathways may have deleterious conse-
quences, particularly in patients with asthma. Re-
cently, long-term use of β-agonists has been linked to
an increased rate of deaths due to asthma.1 Data from
a large placebo-controlled US study (the SMART
study2;) showed a small but significant increase in
asthma-related deaths in patients receiving sal-
meterol (13 deaths out of 13176 patients treated for
28 weeks) versus placebo (3 deaths out of 13179 pa-
tients). As a result, the US Food and Drug Admini-
stration has recently issued recommendations on
how long-acting β2-agonists (LABAs) should be used
to treat asthma, placing a safety warning on LABAs
used alone or in combination with inhaled corticoster-
oids (ICS).3
Pharmacogenetics could be a useful means of opti-
mizing bronchodilator therapy in patients with
asthma or COPD. Much of the interest in genetic
control of the airway responses to β-agonists has fo-
cused on the ADRB2 gene; some ADRB2 polymor-
phisms result in changes in the amino acid sequence
of the β2AR, leading to alterations of its properties,
possibly representing a risk factor for adverse re-
sponses to β-agonist therapy.4-6 This review discusses
the current understanding of the association of
ADRB2 polymorphisms with bronchodilator and
bronchoprotective responses to chronic inhaled β2-
agonists. In the future, translation of this knowledge
into clinical guidelines for β2-agonist prescription
may contribute to improvement in the efficacy and
safety of treatment for asthma and COPD.
ADVERSE EFFECTS OFβ2-AGONISTS AND
THEIR POTENTIAL MECHANISMS
Despite the ability of β-agonists to cause immediate
reversal of airway narrowing, concern remains that
regular use of these drugs may be associated with ad-
verse outcomes especially when used to treat patients
with asthma. In animal models of asthma, administra-
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tion of β-agonists induced airway morphologic
changes and bronchial hyperresponsiveness.7,8 In hu-
man studies, regularly scheduled use of inhaled β-
agonists has resulted in loss of asthma control, de-
clines in morning peak flow, longer durations of
asthma exacerbations, rebound airway hyperrespon-
siveness (AHR),9-15 and airway inflammation.16,17 Epi-
demiological studies have demonstrated a positive
correlation between the chronic use of short-acting
β2-agonists and asthma mortality.18,19 Recently, a
large trial with the long-acting β2-agonist, salmeterol,
was stopped because of increased death rates and se-
rious “asthma related” events among the African
American subgroup on long-term salmeterol.2
The potential mechanisms for higher risk of death
and life-threatening adverse effects are unclear but
may include masking increasing inflammation and
delaying awareness of worsening asthma.20 The com-
mon explanation for these observations is that the ad-
verse effects of regular β-agonist therapy are related
to desensitization of the β2AR,10,11,13,21-23 a character-
istic of many membrane-associated receptors after
high-dose or repeated exposure to agonists. “Endoge-
nous downregulation” is an issue.24 Paradoxically, for
reasons determined by genotype, the acute response
to pharmacologic concentrations of β2-agonists in
vivo may be greatest in patients harboring receptors
that are theoretically resistant to downregulation with
exposure to physiologic concentrations of endoge-
nous catecholamine.25 This may explain why acute re-
sponses in vivo are greater in individuals homozy-
gous for Arg16,26,27 whereas the same genotype pre-
disposes to adverse outcomes, possibly resulting
from enhanced pharmacologically induced down-
regulation during long-term β-agonist exposure.28-30
In this regard, proinflammatory cytokines in the asth-
matic condition known to cause heterologous desen-
sitization of the β2AR31 might also be of importance.
Alternatively, emerging data suggest proinflamma-
tory effects associated with persistent β2AR activation
resulting in increased airway inflammation and hyper-
responsiveness, cardinal features of asthma. Studies
using transgenic mice overexpressing airway smooth
muscle β2AR revealed that persistent high-level acti-
vation of the β2AR leads to increased expression of
phospholipase C-β in airway smooth muscle and may
augment the effects of bronchoconstrictors such as
acetylcholine, histamine, and leukotrienes.32 Another
study provided evidence that prolonged exposure of
cultural human airway smooth muscle cells to β2-
agonists auguments procontractile signaling path-
ways elicited by thrombin, bradykinin and histamine.
This study indicated repetitive β2-agonist use lead to
sensitization of excitation-contraction signaling path-
ways as a result of reduced expression of Regulator of
G protein signaling 5 (RGS5), which is an inhibitor of
G-protein-coupled receptor (GPCR) activity.33 Thus,
the β2AR regulates constrictive signals, affecting
bronchomotor reactivity by means other than direct
dilatation. Chronic administration of β-blockers also
attenuated airway responsiveness and eosinophilic in-
flammation both in a murine model of asthma34 and
in patients with asthma,35 suggesting that persistent
activity of the airway β2AR negatively impacts in-
creased airway inflammation and remodeling in
asthma. An animal study also showed that β2AR sig-
naling is required for development of mucin produc-
tion, airway hyperresponsiveness, and inflammatory
cellular infiltrates in a murine model of asthma.36
Continuous use of β-agonists as asthma monotherapy
also has the potential to increase type 2 cytokine-
mediated airway inflammation.37,38 β2-Agonists also
significantly enhanced the cytokine-induced TSLP
production by primary human lung tissue cells.39 In-
terestingly, an increased risk of severe exacerbation
of respiratory symptoms as well as death in some pa-
tients using LABAs has been reported only for the
treatment of asthma but not for COPD. This may indi-
cate that β2AR agonism on airway hyperresponsive-
ness and allergic inflammation rather than agonist-
induced receptor downregulation represents a very
probable mechanism of the adverse effects associated
with long-term β2-agonists therapy.
ADRB2 GENE POLYMORPHISMS
The ADRB2 gene is a small intronless gene on chro-
mosome 5q31-q32,40 a region that is genetically
linked to asthma and related phenotypes.41,42 Reihaus
et al.43 originally described 9 coding polymorphisms
in ADRB2, 4 of which (Gly16Arg, Gln27Glu, Val34
Met, and Thr164Ile) create nonsynonymous changes
in the amino acid sequence. Drysdale et al.4 de-
scribed the molecular haplotypic structure of the
ADRB2 gene in several ethnic groups; 13 polymor-
phisms were organized into 12 haplotypes out of the
theoretically possible 8192 combinations, and deep
divergence in the distribution of some haplotypes
was noted in white, black American, Asian, and
Hispanic-Latino groups with differences of more than
20-fold among the frequencies of the 4 major haplo-
types. Recently, comprehensive resequencing of a
5.3-kb region of ADRB2 in 669 African American and
white participants has identified 49 polymorphisms.
These polymorphisms are in the regulatory regions,
including the promoter region and the 3’-UTR. They
contribute to haplotypic structure and genetic asso-
ciation with asthma-related phenotypes.44 Screening
of the ADRB2 gene in Japanese participants has also
revealed 15 single nucleotide polymorphisms (SNPs)
within the 3-kb promoter and 1.2-kb structural re-
gions.45
FUNCTIONAL RELEVANCE OF ADRB2 GENE
POLYMORPHISMS
Functional responses in recombinant cell systems
and primary cultured airway cell lines have revealed
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altered downregulation profiles for the Arg16Gly and
Gln27Glu variants of this receptor and altered cou-
pling with the Thr164Ile variant.46-48 In addition, sev-
eral more polymorphisms have been identified in the
ADRB2 5’ promoter region, one of which is localized
to the 5’ leader cistron (5’LC), a signaling peptide in-
volved in regulation of β2AR translation.49 In recom-
binant cells, 5’LC-Arg19Cys (allelic frequency about
60% in white individuals) leads to higher β2AR ex-
pression49 and β2AR promoter-driven luciferase activ-
ity50 than in wild type cells. Studies of the genetic ef-
fects of the ADRB2 polymorphisms on agonist-
induced β2AR desensitization in airway smooth mus-
cle cells48,51 and mast cells52 in vitro and in lympho-
cytes ex vivo53,54 have yielded conflicting results: Arg
16Gly and Gln27Glu polymorphisms have been asso-
ciated with both decreased and increased agonist-
induced desensitization of the β2AR-mediated cyclic
adenosine monophosphate (cAMP) response48,51 or
with downregulation of the receptor.48,52-54
Alterations in function due to β2AR allelic vari-
ations might result from a combination of polymor-
phisms rather than from a single polymorphism.4
Linkage disequilibrium may account for conflicting
results regarding the functional effects of these poly-
morphisms when considered in isolation.48,51-54
Haplotype may predict the clinical phenotype better,
particularly if each polymorphism included has a
functional role and when 1 polymorphism operates in
a direction opposite to the other.55 Liggett et al. re-
cently constructed 8 common haplotypes derived
from 26 polymorphisms. Whole-gene transfection
was performed with COS-7 cells and revealed 4 haplo-
types with increased cell surface β2AR protein ex-
pression as compared with the others. Agonist-
promoted downregulation of β2AR protein expression
was also haplotype-dependent, and was found to be
increased for 2 haplotypes.56
ADRB2 GENE POLYMORPHISMS AND RE-
SPONSES TOβ-AGONISTS
A) ACUTE BRONCHODILATOR RESPONSES
The clinical response to β-agonists in the treatment of
asthma shows a high degree of interindividual vari-
ation that is not adequately explained by ethnicity,
age,27,57 or baseline lung function.1,58 A recent analy-
sis estimated that roughly 60% of the population vari-
ance in the forced expiratory volume in 1 second
(FEV1) response to albuterol was attributable to ge-
netic variations,59 which might be caused in part by
variations in the ADRB2 gene polymorphisms. Mar-
tinez et al.26 found that children homozygous for
Arg16 were 5.3 times more likely to show reversibil-
ity to albuterol than were those homozygous for
Gly16. Heterozygous Gly16Arg16 children showed
intermediate responses to albuterol, whereas vari-
ations at the Gln27Glu polymorphism had no signifi-
cant effect. A reduced response to β-agonist therapy
in participants homozygous for Gly16 has been repli-
cated in other studies.53,60,61 We studied a Ban-I
RFLP and subsequently demonstrated that it coin-
cided with SNP +523 in 58 individuals from 4 Japa-
nese families62; this variant appeared to be associated
with bronchodilator responsiveness. The increases in
FEV1 after inhalation of procaterol hydrochloride
were also measured in 81 Japanese patients with
moderate to severe asthma (mean age of the partici-
pants was 54 years, and 47% were smokers).63 Multi-
variate linear regression analysis showed that in-
creased responsiveness to procaterol was correlated
with the number of Arg16 alleles, indicating that the
ADRB2 Arg16Gly polymorphism was associated with
bronchodilator responsiveness to β2-agonists even in
elderly asthmatic patients and smokers.
Drysdale et al. reported an effect of haplotype pairs
on acute bronchodilator responses to albuterol.4 Re-
cent reports on patients with asthma, however, re-
ported no significant relationship between haplotype
pairs and bronchodilator response.44,64 The study by
Choudhry et al.61 provides insight into potential eth-
nic group differences in pharmacogenetic effects (Ge-
netics of Asthma in Latino Americans [GALA] Study).
The investigators found that in a group of 274 Mexi-
can and 393 Puerto Rican families recruited on the
basis of having a child with asthma, the Arg16 allele
was significantly associated with increased bronchial
reversibility in the combined population; however,
when stratified by ancestral country of origin, the as-
sociation remained significant only in the Puerto Ri-
can group. The investigators found that bronchodila-
tor responses were greater in the group with a spe-
cific haplotype. The Childhood Asthma Management
Program (CAMP), another large family-based study
consisting primarily of participants with mild
asthma,5 included genotype data on 8 ADRB2 SNPs
in 700 complete trios (mother, father, and child with
asthma). The same haplotype was associated with
lower bronchodilator response measures in both the
CAMP participants and the GALA Puerto Rican par-
ticipants. These data, however, contrast with the re-
port by Drysdale et al.,4 in which the same haplotype
was associated with lower measures of bronchodila-
tor drug responsiveness. Furthermore, in the GALA
study, no association was observed between Arg16
Gly genotypes and drug responsiveness among Mexi-
cans with asthma. These discrepancies may be partly
explained by different linkage disequilibrium patterns
in the different study groups or by the interaction of
socioeconomic and other environmental factors with
genetic background.
B) REGULAR USES
The genetic effects of the ADRB2 gene seem to de-
pend on the duration of therapy, and the genetic ef-
fects of long-term use cannot be predicted from the
acute effects. In an Asthma Clinical Research Net-
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Fig.　1　Dissociation between bronchodilator and bronchoprotective effect of ICS/LABA. (Left) Morning PEF in patients with 
asthma while assigned to receive treatment with ICS plus LABA or placebo, by genotype. Adapted from Reference 69. 
(Right) Methacholine responsiveness in participants while assigned to receive treatment with inhaled corticosteroid plus sal-
meterol or placebo, by genotype. Adapted from Reference 69.
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(ACRN) study,28 participants with asthma who were
homozygous for Arg16 and treated with regular,
short-acting β-agonists experienced significant de-
clines in PEFR compared with Gly16 homozygous
participants. Taylor et al. observed similar effects as
well as increased exacerbations in Arg16 homozy-
gous participants on regular albuterol treatment.
However, they did not report changes in Arg16
Arg16 participants receiving intermittent albuterol or
the long-acting β-agonist salmeterol.29 The first pro-
spective, randomized clinical trial examining pharma-
cogenetic responses in asthma confirmed the poorer
response of Arg16Arg16 individuals to regular short-
acting β2-agonist therapy.30 In contrast, Gly16Gly16
participants receiving regular albuterol experienced
improvement in peak flow rates and fewer daily
asthma symptoms. In that study,30 the adverse effects
of regular β-agonist use could be observed even
weeks after their withdrawal, at a time when β2AR de-
sensitization should be resolved. If regular use of β-
agonists negatively impacts the balance of factors
contributing to airway inflammation or airway remod-
eling in asthma, it could have long-term conse-
quences. This contention is supported by the fact that
in studies of regular use of β-agonists adverse effects
have been reported only in participants homozygous
for Arg16, which is rather resistant to desensitization
in vitro.
In addition, a report on the responses to salmeterol
in 2 ACRN trials found that Arg16Arg16 participants
had decreased responses to salmeterol in the pres-
ence or absence of concurrent ICS.65 The Arg16Gly
polymorphism is common in the Japanese population,
and we retrospectively analyzed the outpatient re-
cords of asthmatic patients.66 Twenty-seven patients
with the Arg16Arg16 genotype and 35 patients with
the Gly16Gly16 genotype regularly used β2-
agonists, whereas 37 patients with Arg16Arg16
genotype and 29 patients with Gly16Gly16 genotype
used them as needed. During follow-up periods of at
least 6 months at Hokkaido University Hospital, long-
term bronchodilator responses were assessed using 3
indices: (a) improvement in FEV1 (DeltaFEV1 [mL]),
(b) DeltaFEV1FEV1 at the initial visit, and (c) Del-
taFEV1predicted FEV1. In patients with the Gly16
Gly16 genotype, those who regularly used β2-
agonists had greater improvement in FEV1 in every
index (p = 0.027-0.041) than did those who used them
as needed. In contrast, in patients with the Arg16
Arg16 genotype, regular usage of β2-agonists did not
yield greater improvement in FEV1 when compared
with as-needed β2-agonist usage. This finding sug-
gests that Gly16Gly16 and Arg16Arg16 genotype
responses to regular usage of β2-agonists may differ
in Japanese patients with asthma. The relevance of
ADRB2 haplotypes, rather than single polymor-
phisms, was not assessed in this study.
In contrast, in a small retrospective analysis of clini-
cal trial data, no genotype-related adverse effects
were identified.67 In a larger retrospective study68 us-
ing 2650 participants with moderate asthma, of whom
430 had the Arg16 genotype, no association between
treatment with either salmeterol or formoterol and
clinical outcomes was identified after stratification by
ADRB2 genotype or relevant haplotypes. However,
the patients included in both studies were prese-
lected to benefit from a long-acting bronchodilator in
terms of baseline reversibility, thus perhaps exagger-
ating the effect of the long-acting β-agonist in these
participants.
In a prospective study in a genotype-stratified popu-
lation in which salmeterol was added to inhaled corti-
costeroid therapy,69 87 mild-to-moderate asthmatic
patients were stratified by Arg16Gly genotypes. The
improvement in morning PEFR with salmeterol ther-
apy was similar for Arg16 and Gly16 homozygous pa-
tients. Half of the Arg16Arg16 patients, however, ex-
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Fig.　2　Infl uence of the ADRB2 genotype on bronchodilator responses to ICS/LABA both in Japanese 
and African American populations. (Left) Genetic infl uence of the Arg16Gly polymorphism on ΔFEV1 ac-
cording to regular usage of β2-agonists in Japanese patients with asthma. Signifi cance of 0.075 was 
shown for the interaction between genotypes and regular use of β2 agonist. Adapted from Reference 66. 
(Right) Morning PEF in African-American patients with asthma while assigned to receive treatment with 
ICS plus LABA or placebo, by genotype. Adapted from Reference 69.
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perienced worsening of methacholine responsiveness
despite improvement in their airway function by addi-
tion of LABA to ICS (Fig. 1). This finding clearly indi-
cated the dissociation between the bronchodilator
and bronchoprotective effects of LABA, which may
underlie the significant deterioration in asthma con-
trol caused by long-term usage of LABA. In the post
hoc analysis, African American individuals with the
Arg16Arg16 genotype did not benefit from the addi-
tion of LABA to ICS, which was a finding identical to
that of our previous report66 (Fig. 2). Given that
ADRB2 allele frequencies and genotype distributions
in Japanese participants were similar to those of Afri-
can Americans,4 the LARGE trial may suggest that
patients with Arg16Arg16 are susceptible to an in-
creased risk of serious asthma outcomes owing to
long term use of LABA. LABA therapy might pro-
mote a “high level of current control” without improv-
ing stability and the risk of exacerbations in patients
with particular genotypes.
Bleecker and associates70 recently demonstrated
that asthmatic patients stratified by Arg16Gly geno-
type showed similar clinical responses to salmeterol
alone or in combination with fluticasone. Meanwhile,
they confirmed that the use of salmeterol signifi-
cantly increases the risk of loss of asthma control, as
suggested by the observation that 10 of 272 patients
receiving salmeterol alone had an exacerbation, com-
pared with only 1 of 272 patients receiving the ICS
LABA combination, which was statistically signifi-
cant. Furthermore, 1 asthma-related death occurred
during the study in a patient receiving salmeterol
alone. Bleecker et al. also found that patients ho-
mozygous for Arg16 had a significantly higher num-
ber of disease exacerbations during the run-in phases
of the trial.
C) COPD
Chronic obstructive pulmonary disease is character-
ized by a persistent airflow limitation that is not fully
reversible; however, reversibility of airflow limitations
in response to a bronchodilator is an important com-
ponent of COPD. The degree of reversibility of air-
flow obstruction shown by patients with COPD varies
considerably.71 In a recent study of 274 patients with
COPD,72 we showed that bronchodilator response to
salbutamol therapy was associated with a continuous
phenotype in patients, with a wide interindividual
variation. We have reported preliminary evidence, in
patients with COPD, that the Arg16Gly polymor-
phism has a significant physiologic role in regulating
responses to β2-agonists.73 By studying 246 patients
with COPD who were participants in a longitudinal
study of COPD (Hokkaido COPD cohort study), we
compared short-term bronchodilator responses to sal-
butamol according to ADRB2 genotypes at codons 16
and 27. The presence of the Arg16 allele was associ-
ated with lower bronchodilator responses to β2-
agonist inhalation. Log values (postbronchodilator
FEV1-prebronchodilator FEV1) of individuals ho-
mozygous for Gly16 (n = 65), heterozygous for Arg16
Gly16 (n = 106), and homozygous for Arg16 (n = 75)
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were 2.19 ± 0.43 (mean ± SD), 2.09 ± 0.42, and 2.01 ±
0.42, respectively (p < 0.05). The genetic effects of the
Arg16Gly polymorphism were independent of the se-
verity of airflow limitation, age, and smoking status.
The most common Arg16-Gln27 haplotype was also
significantly associated with decreased bronchodila-
tor responses to salbutamol (p < 0.01). Our finding in
patients with COPD is in apparent contradiction with
previous findings26,63 showing that asthmatic patients
carrying Arg16 had significantly greater β2-agonist
responsiveness. It is possible that the mechanisms by
which polymorphisms in the ADRB2 gene determine
responses to β2-agonists in patients with asthma are
different from those among patients with COPD, at
least in part because asthma and COPD have mecha-
nistic difference in their pathobiology, including dif-
ferent genetic and environmental backgrounds.
CONCLUSIONS
Although β2-agonists are effective and safe in most
patients with asthma and COPD, they may be less ef-
fective or potentially harmful in some. Pharmacoge-
netic approaches hold the promise of matching indi-
vidualized treatments to specific genotypes in a way
that minimizes side effects while improving therapeu-
tic outcomes. From the research reported to date,
however, no consensus has been reached on the rela-
tionship between identified ADRB2 genetic variations
and airway responses to β2-agonists, including bron-
chodilation and bronchoprotective effects. Interpreta-
tion of the findings of genetic association studies of
the ADRB2 polymorphisms may be complicated by
inadequate measurement of environmental exposures
such as smoking and by differences in allele and
haplotype frequencies of the ADRB2 gene. The com-
plex genotype-response effects observed limit their
clinical applications. Future large prospective studies
should take account of ADRB2 haplotypic variations,
possible gene-gene interactions, as well as gene-
environment interactions. More insight into how al-
terations in the expression or function of the gene af-
fect clinical phenotypes is necessary to help us trans-
late ADRB2 genetic information into application in
clinical practice.
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